Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJun 02, 2009	Versartis, Inc. Completes Series A Funding of $11 Million [€7.9 M] in a Joint Venture between Index Ventures and Amunix, Inc. Versartis, Inc. Completes Series A Funding of $11 Million [€7.9 M] in a Joint Venture between Index Ventures and Amunix, Inc. Redwood City, CA – June 2, 2009 – Versartis, Inc. announced today that it has closed a Series A financing with an initial commitment of $11 million [€7.9 M] from Index	View HTML Versartis, Inc. Completes Series A Funding of $11 Million [€7.9 M] in a Joint Venture between Index Ventures and Amunix, Inc. 18.6 KB
Toggle SummaryJun 05, 2009	Versartis Publishes Preclinical Abstracts for Two Product Candidates at 2009 American Diabetes Association Scientific Sessions New Company Focusing on Extending Half Life of Drugs for Metabolic and Endocrine Diseases	View HTML Versartis Publishes Preclinical Abstracts for Two Product Candidates at 2009 American Diabetes Association Scientific Sessions 18.7 KB
Toggle SummaryJun 10, 2009	Versartis Presents Positive Preclinical Data on Two Product Candidates at ENDO 09 New Company Focusing on Extending Half-Life of Drugs for Metabolic and Endocrine Diseases	View HTML Versartis Presents Positive Preclinical Data on Two Product Candidates at ENDO 09 16.6 KB
Toggle SummaryAug 17, 2009	SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes AMSTERDAM, August 17 - SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel	View HTML SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes 15.3 KB
Toggle SummarySep 14, 2009	Versartis to Provide Update on Product Pipeline at Two Technology Conferences New Technology Being Used to Extend Half-Life of Drugs for Metabolic and Endocrine Diseases	View HTML Versartis to Provide Update on Product Pipeline at Two Technology Conferences 14.9 KB
Toggle SummarySep 23, 2009	Versartis Presents Preclinical Data for Novel Type 2 Diabetes Drug New Compounds Extend Half-Life for Monthly Dosing	View HTML Versartis Presents Preclinical Data for Novel Type 2 Diabetes Drug 15.2 KB
Toggle SummaryNov 15, 2009	XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics Redwood City and Mountain View, CA – November 15, 2009 – Amunix, Inc. and Versartis, Inc. announced today that the scientific journal Nature Biotechnology	View HTML XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics 20 KB
Toggle SummaryJan 11, 2010	Versartis to Present at Biotech Showcase in San Francisco – Company Focused on Extending the Half-Life of Drugs for Metabolic and Endocrine Diseases –	View HTML Versartis to Present at Biotech Showcase in San Francisco 15 KB
Toggle SummaryMar 26, 2010	Versartis to Present New Data at International Congress on Endocrinology - Posters will Illustrate Progress of Company’s Drugs for Metabolic and Endocrine Diseases -	View HTML Versartis to Present New Data at International Congress on Endocrinology 17.3 KB
Toggle SummaryApr 14, 2010	Paul Westberg Joins Versartis as Senior Vice President, Business Development - Focus on Transactions for Novel Therapeutics –	View HTML Paul Westberg Joins Versartis as Senior Vice President, Business Development 15.7 KB